Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protagonist Therapeutics Q4 2023 GAAP EPS $0.44 Beats undefined Estimate, Sales $60.00M Beat $40.00M Estimate

Author: Benzinga Newsdesk | February 27, 2024 06:40pm
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of undefined by Infinity percent. The company reported quarterly sales of $60.00 million which beat the analyst consensus estimate of $40.00 million by 50.00 percent.

Posted In: PTGX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist